Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Well 1: Bepirovirsen in Chronic Hepatitis B
NCT05630807Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Bepirovirsen with Placebo (2 arms). Primary endpoint: Functional Cure at 72 weeks. Started Dec 2022; status: completed.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05630807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630807.